EUCTR2009-009503-19-BE进行中（未招募）1 期
A prospective, open label, non-randomised, clinical trial to determine if natalizumab (Tysabri) improves ambulatory measures in relapsing remitting multiple sclerosis (RRMS) patients. - TIMER
Biogen Idec International GmbH0 个研究点目标入组 200 人开始时间: 2009年5月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Must give written informed consent and provide all authorizations required by local law (e.g., Protected Health Information [PHI])
- •2. Men or women between 18 and 60 years of age, inclusive
- •3. Must have EDSS = 5.5 at baseline.
- •4. Must be able to walk at least 100m without assistive devices
- •5. Must be natalizumab naïve
- •6. Must have a documented diagnosis of a relapsing remitting form of MS as defined by the revised McDonald Committee criteria (Polman, 2005)
- •7. Must have had a recent MRI (within 3 months from baseline)
- •8. Must have had at least 1 relapse in the previous year and must satisfy the locally approved therapeutic indications for TYSABRI®. If TYSABRI® is not yet approved in a specific country, patients must fulfill the following criteria:
- •Patients with high disease activity despite treatment with a beta-interferon defined as patients who have failed to respond to a full and adequate course of a beta-interferon. Patients must have had at least 1 relapse in the previous year while on therapy, and have at least 9 T2-hyperintense lesions in cranial MRI or at least 1 Gd-enhancing lesion.
- •Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined as patients who have had 2 or more disabling relapses in one year and 1 or more Gd-enhancing lesions on brain MRI or significant increase in T2 lesions as compared to a previous MRI
- •9. Must be stable in disability for at least 30 days prior to enrollment to the study
- •10. Must be stable in symptomatic management of the disease, specifically spasticity, depression and fatigue for at least 30 days prior to enrollment to the study
- •11. Must be considered by the Investigator to be free of signs and symptoms suggestive of PML based on medical history, physical examination, or laboratory testing.
- •12. Must be willing to discontinue and remain free from concomitant immunosuppressive or immunomodulatory treatment (including IFN beta and GA) while being treated with natalizumab during the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Medical History:
- •1. Onset of a relapse within 50 days prior to first infusion
- •2. Considered by the Investigator to be immunocompromised, based on medical history, physical examination, or laboratory testing or due to prior immunosuppressive treatment
- •3. History of, or available abnormal laboratory results indicative of, any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric (including major depression), renal, and/or other major disease that would preclude the administration of a recombinant humanized antibody immunomodulating agent. The Investigator must re-review the subject’s medical fitness for participation and consider any diseases that would preclude treatment.
- •4. History of malignancy (subjects with basal cell carcinoma that has been completely excised prior to study entry remain eligible)
- •5. Known history of human immunodeficiency virus infection or hematological malignancy
- •6. History of organ transplantation (including anti-rejection therapy)
- •7. A clinically significant infectious illness (e.g., cellulitis, abscess, pneumonia, septicemia) within 30 days prior to the Screening Visit.
- •Treatment History:
- •8. Treatment with immunosuppressant medications (e.g., mitoxantrone, cyclophosphamide, cyclosporine, azathioprine, methotrexate) within 6 months prior to Screening
- •Miscellaneous
- •9. Female subjects who are not postmenopausal for at least 1 year, surgically sterile (does not include tubal ligation), or willing to practice effective contraception (as defined by the Investigator) during the study
- •10. Women who are breastfeeding, pregnant, or planning to become pregnant while on study
- •11. Current enrollment in any other study treatment or disease study
- •12. Unwillingness or inability to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to comply with the study protocol
- •13. Subjects with walking impairment due to causes other than MS
- •14. Other unspecified reasons that, in the opinion of the Investigator and/or Biogen Idec, make the subject unsuitable for enrollment into this study.
研究者
相似试验
尚未招募
4 期
to compare the effectiveness of Methylcobalamin Nasal Spray and Oral Methylcobalamin tablet in B12 deficient patients.CTRI/2020/03/023938Dr Arunansu Talukdar
尚未招募
4 期
To check the effectiveness and safety of Methylcobalamin nasal spray in comparison with oral methylcobalamin tablet and methylcobalamin injection.CTRI/2020/08/027422Dr Dushyant Balat
已完成
4 期
A clinical study to evaluate the effect of Methylcobalamine nasal spray in patients with Vitamin B12 deficiency.CTRI/2020/10/028371Dr Sudhir Kumar
已完成
4 期
A clinical study to evaluate the effect of Methylcobalamine nasal spray in patients with subclinical cobalamin deficiency.CTRI/2020/10/028370Dr Sudhir Kumar
已完成
4 期
Study to compare the efficacy and safety of novel Methylcobalamin Spray with Sublingual Methylcobalamin Tablet in treatment of subjects with vitamin B12 deficiency.CTRI/2024/04/066019Troikaa Pharmaceuticals Limited37